Aster DM Healthcare Limited has informed the Exchange regarding a press release dated May 20, 2025, titled "Press Release for Q4 FY 24-25".
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aster DM Healthcare announced its Q4 and Full Year FY25 results on May 20, 2025. Full year revenue grew 12% year-on-year to ₹4,138 crore, while operating EBITDA jumped 30% to ₹806 crore with margins expanding from 16.8% to 19.5%. Normalized profit after tax (excluding merger-related costs of ₹50 crore) grew 49% to ₹357 crore for the year, and Q4 revenue rose 2% to ₹1,000 crore with a 16% jump in EBITDA to ₹193 crore. The company added around 300 beds during the year, taking total capacity to 5,159 beds, with plans to add another 2,100+ beds to reach ~7,300 beds. The merger with Quality Care India, backed by Blackstone and TPG, has received CCI approval and is expected to close by Q4 FY26.
Strong operational performance with double-digit revenue growth and 270 basis points of margin expansion is positive for shareholders. The pending Quality Care merger, backed by Blackstone's financial strength, could be a significant value driver once it closes in Q4 FY26, though it still requires NCLT and stock exchange approvals.